Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Researchers sought to determine 1-year outcomes in patients being treated with tirzepatide who have atrial fibrillation.

Despite promising adherence and persistence data, tirzepatide dose escalation was slower in the real-world than clinical trials in patients with obesity without T2D. Tirzepatide dose escalation is ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Investigators sourced data for this study from the TriNetX Analytics Research Network database. Patients (N=1,999,881) diagnosed with AF between 2022 and 2024 and who used tirzepatide for diabetes ...

Participants were randomly assigned either to escalation of dulaglutide to 4.5 mg or maximum tolerated dose (MTD), or to ...

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the ...

Compounded tirzepatide contains the same active ingredient as Mounjaro, but its dosage and some ingredients may differ from ...

Tirzepatide decreased participants’ calorie intake by reducing appetite while increasing fat oxidation. However, the drug did not decrease the slowing down of their metabolic rate usually observed ...

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the ...

The drug enhances outcomes in a high-risk patient population with a significant unmet need. Tirzepatide significantly ...